P129, a Pyrazole Ring-containing Isolongifolanone-derivate: Synthesis and Investigation of Anti-glioma Action Mechanism

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jan 6

PMID 38184514

Authors

Yining Jiang

Yunyun Wang

Liyan Zhao

Wenzhuo Yang

Lin Pan

Yang Bai

Yubo Wang

Yunqian Li

Affiliations

Soon will be listed here.

Abstract

Background: Cyclin-dependent kinase-2 (CDK-2) is an important regulatory factor in the G/S phase transition. CDK-2 targeting has been shown to suppress the viability of multiple cancers. However, the exploration and application of a CDK-2 inhibitor in the treatment of glioblastoma are sparse.

Methods: We synthesized P129 based on isolongifolanone, a natural product with anti-tumor activity. Network pharmacology analysis was conducted to predict the structural stability, affinity, and pharmacological and toxicological properties of P129. Binding analysis and CETSA verified the ability of P129 to target CDK-2. The effect of P129 on the biological behavior of glioma cells was analyzed by the cell counting kit-8, colony formation, flow cytometry, and other experiments. Western blotting was used to detect the expression changes of proteins involved in the cell cycle, cell apoptosis, and epithelial-mesenchymal transition.

Results: Bioinformatics analysis and CETSA showed that P129 exhibited good intestinal absorption and blood-brain barrier penetrability together with high stability and affinity with CDK-2, with no developmental toxicity. The viability, proliferation, and migration of human glioma cells were significantly inhibited by P129 in a dose- and time-dependent manner. Flow cytometry and western blotting analyses showed G/G arrest and lower CDK-2 expression in cells treated with P129 than in the controls. The apoptotic ratio of glioma cells increased significantly with increasing concentrations of P129 combined with karyopyknosis and karyorrhexis. Apoptosis occurred via the mitochondrial pathway.

Conclusion: The pyrazole ring-containing isolongifolanone derivate P129 exhibited promising anti-glioma activity by targeting CDK-2 and promoting apoptosis, indicating its potential importance as a new chemotherapeutic option for glioma.

Citing Articles

Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells.

Taheri E, Raeeszadeh-Sarmazdeh M Oncotarget. 2025; 16:118-130.

PMID: 40019229 PMC: 11870142. DOI: 10.18632/oncotarget.28691.

References

Huang H, Regan K, Lou Z, Chen J, Tindall D . CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006; 314(5797):294-7. DOI: 10.1126/science.1130512. View

Suski J, Braun M, Strmiska V, Sicinski P . Targeting cell-cycle machinery in cancer. Cancer Cell. 2021; 39(6):759-778. PMC: 8206013. DOI: 10.1016/j.ccell.2021.03.010. View

Musgrove E, Hunter L, Lee C, Swarbrick A, Hui R, Sutherland R . Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2. J Biol Chem. 2001; 276(50):47675-83. DOI: 10.1074/jbc.M106371200. View

Khan M, Alam M, Verma G, Akhtar W, Akhter M, Shaquiquzzaman M . The therapeutic voyage of pyrazole and its analogs: A review. Eur J Med Chem. 2016; 120:170-201. DOI: 10.1016/j.ejmech.2016.04.077. View

Faber A, Chiles T . Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle. 2007; 6(23):2982-9. DOI: 10.4161/cc.6.23.4994. View

Bhardwaj P, Biswas G, Mahata N, Ghanta S, Bhunia B . Exploration of binding mechanism of triclosan towards cancer markers using molecular docking and molecular dynamics. Chemosphere. 2022; 293:133550. DOI: 10.1016/j.chemosphere.2022.133550. View

Au-Yeung G, Lang F, Azar W, Mitchell C, Jarman K, Lackovic K . Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res. 2016; 23(7):1862-1874. PMC: 5364079. DOI: 10.1158/1078-0432.CCR-16-0620. View

Nicholson J, Fine H . Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discov. 2021; 11(3):575-590. DOI: 10.1158/2159-8290.CD-20-1474. View

Pierson-Mullany L, Lange C . Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004; 24(24):10542-57. PMC: 533997. DOI: 10.1128/MCB.24.24.10542-10557.2004. View

10.

Wang Y, Wu C, Zhang Q, Shan Y, Gu W, Wang S . Design, synthesis and biological evaluation of novel β-pinene-based thiazole derivatives as potential anticancer agents via mitochondrial-mediated apoptosis pathway. Bioorg Chem. 2018; 84:468-477. DOI: 10.1016/j.bioorg.2018.12.010. View

11.

Li H, Lei B, Xiang W, Wang H, Feng W, Liu Y . Differences in Protein Expression between the U251 and U87 Cell Lines. Turk Neurosurg. 2016; 27(6):894-903. DOI: 10.5137/1019-5149.JTN.17746-16.1. View

12.

Li Y, Yin W, Wang X, Zhu W, Huang Y, Yan G . Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proc Natl Acad Sci U S A. 2007; 104(33):13438-43. PMC: 1940034. DOI: 10.1073/pnas.0701990104. View

13.

Dragnev K, Pitha-Rowe I, Ma Y, Petty W, Sekula D, Murphy B . Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res. 2004; 10(7):2570-7. DOI: 10.1158/1078-0432.ccr-03-0271. View

14.

Mu B, Li Y, Ye N, Liu S, Zou X, Qian J . Understanding apoptotic induction by Sargentodoxa cuneata-Patrinia villosa herb pair via PI3K/AKT/mTOR signalling in colorectal cancer cells using network pharmacology and cellular studies. J Ethnopharmacol. 2023; 319(Pt 3):117342. DOI: 10.1016/j.jep.2023.117342. View

15.

Niland S, Riscanevo A, Eble J . Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2022; 23(1). PMC: 8745566. DOI: 10.3390/ijms23010146. View

16.

Scaltriti M, Eichhorn P, Cortes J, Prudkin L, Aura C, Jimenez J . Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011; 108(9):3761-6. PMC: 3048107. DOI: 10.1073/pnas.1014835108. View

17.

Ma C, Wang Y, Dong F, Wang Z, Zhao Y, Shan Y . Synthesis and antitumor activity of isolongifoleno[7,8-d]thiazolo[3,2-a]pyrimidine derivatives via enhancing ROS level. Chem Biol Drug Des. 2019; 94(2):1457-1466. DOI: 10.1111/cbdd.13522. View

18.

Opyrchal M, Salisbury J, Iankov I, Goetz M, McCubrey J, Gambino M . Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 2014; 45(3):1193-9. PMC: 4121417. DOI: 10.3892/ijo.2014.2523. View

19.

Kawakami M, Mustachio L, Rodriguez-Canales J, Mino B, Roszik J, Tong P . Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst. 2017; 109(6). PMC: 6059250. DOI: 10.1093/jnci/djw297. View

20.

Sun Y, Thakur K, Hu F, Zhang J, Wei Z . Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/ CDK 2 pathway and activating mitochondria-dependent pathway. Pharmacol Res. 2019; 152:104616. DOI: 10.1016/j.phrs.2019.104616. View